Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ: VRDN )

18.90 +0.45 (+2.44%)
Streaming Delayed Price Updated: 12:46 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
Why Are Viridian Therapeutics Shares Falling Today
Viridian Therapeutics Inc (NASDAQ: VRDN) released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another breakdown of the biggest pre-market stock movers as we check out all of the shares rising and falling on Tuesday! 
Via InvestorPlace
JetBlue Airways, VOXX International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
11 Analysts Have This to Say About Viridian Therapeutics
Via Benzinga
Analyst Ratings for Viridian Therapeutics
Via Benzinga
Recap: Viridian Therapeutics Q1 Earnings
Via Benzinga
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
From Viridian Therapeutics, Inc.
Via Business Wire
Earnings Outlook For Viridian Therapeutics
Via Benzinga
Expert Ratings for Viridian Therapeutics
Via Benzinga
Analyst Expectations for Viridian Therapeutics's Future
Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Analyst Expectations for Viridian Therapeutics's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Viridian Therapeutics Earnings Preview
Via Benzinga
The Latest Analyst Ratings for Viridian Therapeutics
Via Benzinga
Viridian's Thyroid Eye Disease Candidate Shows Promise At Lower Doses
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Viridian Therapeutics' Lead Product Has An Opportunity To Differentiate, Analyst Sees 85% Upside
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.